Cargando…

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost

PURPOSE: The preservative benzalkonium chloride (BAK) may adversely affect ocular surface health. This study evaluated symptoms of ocular surface disease (OSD) in patients previously treated with a BAK-preserved therapy to lower their intraocular pressure, who either continued that therapy or switch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katz, Gregory, Springs, Clark L, Craven, E Randy, Montecchi-Palmer, Michela
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993125/ https://www.ncbi.nlm.nih.gov/pubmed/21151330 http://dx.doi.org/10.2147/OPTH.S14113

Ejemplares similares

Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
por: Kumar, Suresh, et al.
Publicado: (2019)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Mirza, Sophia K, et al.
Publicado: (2010)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado, Ahmed Salah, et al.
Publicado: (2012)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Travoprost in the management of open-angle glaucoma and ocular hypertension
por: Denis, Philippe, et al.
Publicado: (2007)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma
por: Tomić, Martina, et al.
Publicado: (2013)

The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension
por: Misiuk-Hojlo, Marta, et al.
Publicado: (2018)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella, Fernanda, et al.
Publicado: (2012)

Effect of benzalkonium chloride–free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
por: Lopes, Joao F., et al.
Publicado: (2015)

Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis
por: Harasymowycz, Paul, et al.
Publicado: (2021)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: Henry, J Charles, et al.
Publicado: (2008)

BAK-up: the receptor kinase BAK-TO-LIFE 2 enhances immunity when BAK1 is lacking
por: Fallahzadeh-Mamaghami, Vahid, et al.
Publicado: (2023)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Suzuki, Emilio Rintaro, et al.
Publicado: (2010)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy
por: Fain, Joel M, et al.
Publicado: (2011)

Playing FullBAK
por: Walensky, Loren D.
Publicado: (2013)

Cancer chemoresistance and BAK
por: Fox, Joanna L.
Publicado: (2015)

Robust autoactivation for apoptosis by BAK but not BAX highlights BAK as an important therapeutic target
por: Iyer, Sweta, et al.
Publicado: (2020)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Teus, Miguel A, et al.
Publicado: (2009)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner, S Fabián, et al.
Publicado: (2019)

Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost
por: Kumar, Suresh, et al.
Publicado: (2020)

Bak activators get in the groove
por: Leslie, Mitch
Publicado: (2011)

BAK additive influence on results
por: Shah, Rupali D, et al.
Publicado: (2013)

The great migration of Bax and Bak
por: Edlich, Frank
Publicado: (2015)

BÄK: Zehn-Punkte-Plan
por: Landschek, Ines
Publicado: (2020)

BAK multimerization for apoptosis, but not bid binding, is inhibited by negatively charged residue in the BAK hydrophobic groove
por: Azad, Abul, et al.
Publicado: (2013)

Cost–Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
por: Kim, Dai Woo, et al.
Publicado: (2021)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão, Marcelo Lopes da Silva, et al.
Publicado: (2014)

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
por: Wang, Tao, et al.
Publicado: (2022)

The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
por: Tokuda, Naoto, et al.
Publicado: (2015)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
por: Dai, Haiming, et al.
Publicado: (2011)

Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization
por: Pang, Yuan-Ping, et al.
Publicado: (2012)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1u8f3dk8iu2rj8bhjbmavr8b66